Long-term prognosis following acute coronary syndromes: a prospective observational study of an unselected group treated in the 24/7 cardiac catheterisation laboratory at a university hospital

2018 ◽  
pp. 755-763 ◽  
Author(s):  
Marcin Grabowski ◽  
Krzysztof J. Filipiak ◽  
Grzegorz Opolski ◽  
Renata Główczyńska ◽  
Monika Gawałko ◽  
...  
Keyword(s):  
Observational Study ◽  
Acute Coronary Syndromes ◽  
Prospective Observational Study ◽  
Cardiac Catheterisation ◽  
University Hospital ◽  
Coronary Syndromes ◽  
Long Term Prognosis ◽  
Unselected Group ◽  
Catheterisation Laboratory

Prevalence, long-term prognosis and medical alternatives for patients admitted for acute coronary syndromes and prasugrel contraindication

2018 ◽  
Vol 270 ◽  
pp. 36-41 ◽  
Author(s):  
Alberto Cordero ◽  
Jose M. García-Acuña ◽  
Moisés Rodríguez-Mañero ◽  
Rosa Agra-Bermejo ◽  
Belen Cid ◽  
...  
Keyword(s):  
Acute Coronary Syndromes ◽  
Coronary Syndromes ◽  
Long Term Prognosis

Prognostication of Cardiovascular Outcomes in Patients with Acute Coronary Syndromes

1970 ◽  
Vol 110 (4) ◽  
pp. 77-80
Author(s):  
M. R. Babarskiene ◽  
J. Vencloviene ◽  
D. Luksiene ◽  
I. Milvidaite
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Acute Coronary Syndromes ◽  
Prognostic Value ◽  
Prognostic Index ◽  
Short Term ◽  
Coronary Syndromes ◽  
Short And Long Term ◽  
Long Term Prognosis

Ischemic heart disease is the leading cause of death in Europe among males over 45 years of age and females older than 65. The aim of the study: to evaluate the informative value of the models in ACS patients using GRACE (GR) risk score, to identify additional informative indicators for short-term and long-term prognosis following ACS, and to evaluate the prognostic reliability of the integrated model. The study included 1491 patients who in 2005 were treated for ACS in the Department of Cardiology, the Hospital of Kaunas University of Medicine. We devised an adjusted prognostic index for making short and long-term prognosis in patients with acute coronary syndromes (STEMI and NSETMI). Following adjustment of the GR scores, the prognostic value improved for STEMI patients. Ill. 2, bibl. 12, tabl. 3 (in English; abstracts in English and Lithuanian).http://dx.doi.org/10.5755/j01.eee.110.4.292

Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study

2004 ◽  
Vol 117 (2) ◽  
pp. 73-81 ◽  
Author(s):  
Kim A Eagle ◽  
Eva Kline-Rogers ◽  
Shaun G Goodman ◽  
Enrique P Gurfinkel ◽  
Alvaro Avezum ◽  
...  
Keyword(s):  
Observational Study ◽  
Acute Coronary Syndromes ◽  
Prospective Observational Study ◽  
Evidence Based ◽  
Coronary Syndromes

scholarly journals Circulating Osteoprotegerin Levels and Long-Term Prognosis in Patients With Acute Coronary Syndromes

2008 ◽  
Vol 51 (6) ◽  
pp. 627-633 ◽  
Author(s):  
Torbjørn Omland ◽  
Thor Ueland ◽  
Anna M. Jansson ◽  
Anita Persson ◽  
Thomas Karlsson ◽  
...  
Keyword(s):  
Acute Coronary Syndromes ◽  
Coronary Syndromes ◽  
Long Term Prognosis

scholarly journals Long-term prognosis of south Asians following acute coronary syndromes

2008 ◽  
Vol 24 (7) ◽  
pp. 585-587 ◽  
Author(s):  
Ramya Raghavan ◽  
Elham Rahme ◽  
Hacene Nedjar ◽  
Thao Huynh
Keyword(s):  
Acute Coronary Syndromes ◽  
South Asians ◽  
Coronary Syndromes ◽  
Long Term Prognosis

scholarly journals Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance

2016 ◽  
Vol 2016 ◽  
pp. 1-5 ◽  
Author(s):  
Peng Yun ◽  
Ai-ming Du ◽  
Xue-jun Chen ◽  
Jing-cheng Liu ◽  
Hu Xiao
Keyword(s):  
Glucose Tolerance ◽  
Impaired Glucose Tolerance ◽  
Acute Coronary Syndromes ◽  
Control Group ◽  
Newly Diagnosed ◽  
Adverse Cardiovascular Event ◽  
Coronary Syndromes ◽  
Long Term Prognosis

Objective. To investigate the effect of acarbose therapy on the long-term prognosis of patients with acute coronary syndromes (ACS) complicating newly diagnosed impaired glucose tolerance (IGT).Methodology. 135 patients hospitalized for ACS who had been newly diagnosed with IGT were randomly assigned to acarbose group (150 mg/day,n=67) or control group (no acarbose,n=68). All cases in each group were given the same elementary treatment. Mean follow-up was 2.3 years. The incidence of major adverse cardiovascular event (MACE) and carotid intima-middle thickness (CIMT) were statistically analyzed.Results. During the mean follow-up of 2.3 years, the risk of recurrent MACE in acarbose group was decreased significantly compared with that in control group (26.67% versus 46.88%,P<0.05); at the same time, thickening of the CIMT was significantly slower than the control group ((1.28 ± 0.42) mm versus (1.51 ± 0.64) mm,P<0.05).Conclusions. Acarbose can effectively reduce the risk of MACE in ACS patients with newly diagnosed IGT, simultaneously retarding the progression of carotid intima-media thickness.

Sign in / Sign up

Export Citation Format

Share Document